Thursday, February 22, 2018
 
 
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Global Intravenous (IV) Iron Drugs Market 2012-2022 by Value, Therapeutic Application & Product Type
 
(February 14, 2018)

DUBLIN, Feb. 14, 2018 /PRNewswire/ --

The "Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application, By Product Type, By Region, By Country (2018 Edition): Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Global market is projected to display a robust growth represented by a CAGR of 11.19% by value during 2017 - 2022, chiefly driven by increase in healthcare spending and rising prevalence of diseases with Iron deficiency, emerging second & third generation IV Iron drugs and growing middle class income group coupled with rising health consciousness.



Over the recent years, the global Intravenous (IV) Iron Drug industry has been driven by the rising high prevalence of Iron Deficiency with unfulfilled need, rising awareness, growing prevalence of diseases leading to severe Iron Deficiency and increasing healthcare expenditure in emerging economies. Globally, the growth in IV Iron drug market is driven by growing middle class population group demanding better drugs to improve lifestyle.

Among the therapeutic application type, nephrology accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with Iron Deficiency and unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.

Scope of the Report




  • Global IV Iron Drug Market, By Value
  • By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
  • By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. I.V. Iron Drug Market Outlook

5. Global I.V. Iron Drug Market: Growth and Forecast

6. North America I.V. Iron Drug Market: Growth and Forecast

7. Europe I.V. Iron Drug Market: Growth and Forecast

8. Asia Pacific I.V. Iron Drug Market: Growth and Forecast

9. ROW I.V. Iron Drug Market: Growth and Forecast

10. Market Dynamics

11. Market Restraints

12. SWOT Analysis - I.V. Iron Drug Market

13. Porter's Five Forces Analysis - I.V. Iron Drug Market

14. Policy and Regulations

15. Company Profiles

  • AMAG Pharmaceuticals Inc
  • Allergan PLC
  • Daiichi Sankyo Company Limited
  • Galenica
  • Nippon Shinyaku CO. LTD
  • Pharmacosmos A/S
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/rqb769/global?w=5

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



Cision View original content:http://www.prnewswire.com/news-releases/global-intravenous-iv-iron-drugs-market-2012-2022-by-value-therapeutic-application--product-type-300598622.html

SOURCE Research and Markets

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Medicine,healthcare,Pregnancy,Surgery,Medication,Pregnancy,Science,Lifestyle,Medical,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • SourceLink Partners with MassMedia Health to Provide Medicare Age-In Data to Healthcare Groups
  • Driven by Boomers, Consumer-Driven Genetic Testing Forecasted to Reach $310 Million
  • Global Mobile Medical Apps Market to Reach $11.22 Billion by 2025, Reports BIS Research
  • U.S. Nebulizer Market Size Worth $435.5 Million By 2025 | CAGR 6.2%: Grand View Research, Inc.
  • Global Cables and Leads for Medical Equipment Industry

    Cancer
  • argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
  • CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
  • Varian Acquires Evinance Innovation, Inc.
  • QCCA Evolves to Become the First National Clinically Integrated Network in Oncology
  • COA: Analysis Shows Virginia Hospitals Benefit From Recent Changes In Medicare Payment
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines